Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with or without AMG 386 in metastatic clear cell renal cell carcinoma
2007-000147-98Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2007
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trebananib and sorafenib in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Amgen. Primary endpoints: Progression-free survival and Safety and tolerability. Started May 2007; status: completed.
02
Drugs
trebananibsorafenib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2007-000147-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000147-98.